Dr. Andrea R Hagemann, M.D., MSCI
Claim this profileWashington University School of Medicine
Area of expertise
Endometrial Cancer
Andrea R Hagemann, M.D., MSCI has run 5 trials for Endometrial Cancer. Some of their research focus areas include:
Cervical Cancer
Andrea R Hagemann, M.D., MSCI has run 4 trials for Cervical Cancer. Some of their research focus areas include:
Affiliated Hospitals
Washington University School Of Medicine
Clinical Trials Andrea R Hagemann, M.D., MSCI is currently running
Behavioral Weight Loss + Progestin
for Endometrial Hyperplasia
Up to 60% of endometrial cancer cases are attributed to obesity, in part because obesity promotes development of atypical endometrial hyperplasia (AEH), and up to 40% of women with AEH go on to develop endometrial cancer. The increasing prevalence of obesity in premenopausal women has resulted in increasing rates of AEH in this age group. Hysterectomy with removal of the fallopian tubes and ovaries is 100% effective in preventing endometrial cancer, but this approach results in infertility. Fertility-sparing treatments exist, such as treatment with oral or intrauterine progestin, but these treatments do not work uniformly and do not combat the underlying cause of endometrial cancer, which is obesity and metabolic syndrome. Additionally, up to 41% of women on progestin eventually experience relapse of AEH or endometrial cancer. Third, many patients have insulin resistance that may worsen with progestin therapy. Thus, to improve treatment of AEH and grade 1 endometrial cancer, prevent and reverse endometrial cancer, and allow women to preserve their fertility, the investigators must integrate an effective weight loss strategy to be given with progestin treatment. It is the hypothesis that premenopausal women with AEH desire uterine preservation will be more likely to have atypia-free uterine preservation at one year if they receive progestin in combination with a behavioral weight loss intervention versus progestin plus enhanced usual care.
Recruiting
1 award
Phase 2
Zanzalintinib + Paclitaxel
for Uterine Cancer
The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.
Recruiting
1 award
Phase 1
5 criteria
More about Andrea R Hagemann, M.D., MSCI
Clinical Trial Related
1 year of experience running clinical trials · Led 16 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Andrea R Hagemann, M.D., MSCI has experience with
- Paclitaxel
- Progestin
- Semaglutide
- Telemedicine Behavioral Weight Intervention
- Levonorgestrel-releasing IUD
- Telemedicine Behavioral Weight Intervention
Breakdown of trials Andrea R Hagemann, M.D., MSCI has run
Endometrial Cancer
Cervical Cancer
Ovarian Cancer
Endometrial Hyperplasia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andrea R Hagemann, M.D., MSCI specialize in?
Andrea R Hagemann, M.D., MSCI focuses on Endometrial Cancer and Cervical Cancer. In particular, much of their work with Endometrial Cancer has involved MSI-H positive patients, or patients who are HER2 positive.
Is Andrea R Hagemann, M.D., MSCI currently recruiting for clinical trials?
Yes, Andrea R Hagemann, M.D., MSCI is currently recruiting for 6 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Andrea R Hagemann, M.D., MSCI has studied deeply?
Yes, Andrea R Hagemann, M.D., MSCI has studied treatments such as Paclitaxel, Progestin, Semaglutide.
What is the best way to schedule an appointment with Andrea R Hagemann, M.D., MSCI?
Apply for one of the trials that Andrea R Hagemann, M.D., MSCI is conducting.
What is the office address of Andrea R Hagemann, M.D., MSCI?
The office of Andrea R Hagemann, M.D., MSCI is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.